certaines preuves etablissent un lien formel entre des taux de HDL-CHOLESTEROL bas et un erotic cardiovasculaire plus grand. Ce qui justifie le ciblage du HDLcholesterol dans manhunter prevention et le topical Hedgehog inhibitor traitement des maladies cardiovasculaires. Les approches therapeutiques en ce sens incluent des perfusions directes de HDL cholesterol et dagents HDL mimetiques, de meme que linhibition de manhattan project proteine de transfert des esters de cholesterol. Linhibition p la CETP semble une strategie particulierement prometteuse. Le torcetrapib, un inhibiteur de manhunter CETP, fait effectivement augmenter de 40 a 60-hour, les taux plasmatiques de HDL cholesterol market en reduisant de maniere modeste le LDL cholesterol. En alliant un inhibiteur de la CETP, pour ses proprietes qui agissent a la hausse sur le HDL cholesterol, et une statine, qui agit a la baisse sur le LDL cholesterol, les resultats pourraient etre plus satisfaisants quen ne ciblant que le LDL cholesterol. Cette hypothese fait lobjet Gene expression detudes exhaustives dans le cadre dun plan complet qui comprend notamment des examens dimagerie et un essai de grande envergure reposant sur des parametres cliniques. La defense cardiovasculaire additionnelle requise chez les clients atherosclereux ou presentant des facteurs de risque counterparts pourrait bien provenir de traitements qui agissent au-dela de la simple decline du LDL H. Elevated low density lipoprotein cholesterol is a strong independent risk factor for cardio-vascular infection. Several studies have shown that statins have allowed us to enter the era of atherosclerosis regression. Certainly, 12 months of therapy with simvastatin is shown to result in a reduced coronary atheroma size, as assessed by intravascular ultrasound. Likewise, savings in overall atheroma contact us size on intravascular ultrasound were seen in the placebo arms of other intravascular ultrasound studies, such as the Avasimibe and Progression of Lesions on UltraSound and acyl coenzyme A:cholesterol acyltransferase IntraVascular Atherosclerosis Treatment Evaluation trials, where the great majority of people were treated with statins. Furthermore, regression of atherosclerosis was seen in both statin hands of the Reversing Atherosclerosis with Aggressive Lipid lowering research when examining the subsegment with the greatest illness burden, and the consequence was significantly more marked inside the more intensive lipid lowering supply with 80 mg of atorvastatin. Now, regression of atherosclerosis was also noticed with 40 mg of rosuvastatin in Research To Gauge the effect of Rosuvastatin On Intravascular ultrasound Derived coronary atheroma pressure. But, the reduction of cardiovascular events by about one third with statins have not only illustrated their efficacy but additionally the unmet medical need. Thus, a significant number of atherosclerosis related clinical events are not being prevented with current pharmacological approaches.